Ibrutinib/Venetoclax Produces Encouraging Results in Relapsed/ Refractory CLL

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [41] UKCLL Forum analysis of patient outcomes post-ibrutinib therapy for relapsed/refractory CLL UK CLL Forum
    不详
    LEUKEMIA & LYMPHOMA, 2020, 61 : 122 - 123
  • [42] PRELIMINARY RESULTS OF A PHASE I/IB STUDY OF IBRUTINIB IN COMBINATION WITH TGR-1202 IN PATIENTS WITH RELAPSED/REFRACTORY CLL OR MCL
    Davids, M. S.
    Kim, H. T.
    Nicotra, A.
    Savell, A.
    Francoeur, K.
    Hellman, J. M.
    Miskin, H.
    Sportelli, P.
    Rado, T.
    Bashey, A.
    Stampleman, L.
    Rueter, J.
    Boruchov, A.
    Arnason, J. E.
    Jacobson, C. A.
    Fisher, D. C.
    Brown, J. R.
    HAEMATOLOGICA, 2016, 101 : 433 - 433
  • [43] Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
    Fuerstenau, Moritz
    Giza, Adam
    Weiss, Jonathan
    Kleinert, Fanni
    Robrecht, Sandra
    Franzen, Fabian
    Stumpf, Janina
    Langerbeins, Petra
    Al-Sawaf, Othman
    Simon, Florian
    Fink, Anna-Maria
    Schneider, Christof
    Tausch, Eugen
    Schetelig, Johannes
    Dreger, Peter
    Boettcher, Sebastian
    Fischer, Kirsten
    Kreuzer, Karl-Anton
    Ritgen, Matthias
    Schilhabel, Anke
    Brueggemann, Monika
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    Cramer, Paula
    BLOOD, 2024, 144 (03) : 272 - 282
  • [44] TGR-1202 in combination with ibrutinib in patients with relapsed or refractory CLL: updated results of a multicenter phase I/Ib study
    Arnason, Jon
    Davids, Matthew S.
    Kim, Haesook T.
    Nicotra, Alyssa
    Savell, Alexandra
    Francoeur, Karen
    Hellman, Jeffrey
    Miskin, Hari
    Sportelli, Peter
    Bashey, Asad
    Stampleman, Laura
    Rueter, Jens
    Boruchov, Adam
    Jacobson, Caron
    Fisher, David
    Brown, Jennifer
    LEUKEMIA & LYMPHOMA, 2017, 58 : 219 - 220
  • [45] Rituximab and High-Dose Methylprednisolone Debulking Prior to Venetoclax for Patients with Relapsed or Refractory CLL
    Choi, Michael Y.
    Heyman, Benjamin
    Pu, Minya
    Pittman, Emily
    Messer, Karen
    Kipps, Thomas J.
    BLOOD, 2022, 140 : 12410 - 12411
  • [46] EHA 2023: New Results on Ibrutinib in Combination with Venetoclax in the First-line Treatment of CLL
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (10) : 447 - 447
  • [47] Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
    Omi, Ai
    Nomura, Fumi
    Tsujioka, Shigeharu
    Fujino, Akiko
    Akizuki, Reiko
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2022, 62 (03) : 136 - 146
  • [48] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Goto, Hideki
    Ito, Satoshi
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Zeng, Jiewei
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy A.
    Izutsu, Koji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 232 - 240
  • [49] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Izutsu, Koji
    Goto, Hideki
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Mukherjee, Nabanita
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy
    Ishizawa, Kenichi
    ANNALS OF ONCOLOGY, 2023, 34 : S1428 - S1428
  • [50] Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Awan, Farrukh T.
    Heerema, Nyla A.
    Hoffman, Corinne
    Lozanski, Gerard
    Maddocks, Kami J.
    Moran, Mollie E.
    Reid, Mark A.
    Lucas, Margaret
    Woyach, Jennifer A.
    Whitlow, W. Thomas
    Jones, Jeffrey A.
    Byrd, John C.
    BLOOD, 2018, 132 (15) : 1568 - 1572
12345